This document is an excerpt from the EUR-Lex website
Document 62022TN0130
Case T-130/22: Action brought on 7 March 2022 — Biologische Heilmittel Heel v EUIPO — Esi (TRAUMGEL)
Case T-130/22: Action brought on 7 March 2022 — Biologische Heilmittel Heel v EUIPO — Esi (TRAUMGEL)
Case T-130/22: Action brought on 7 March 2022 — Biologische Heilmittel Heel v EUIPO — Esi (TRAUMGEL)
OJ C 171, 25.4.2022, p. 34–35
(GA)
OJ C 171, 25.4.2022, p. 44–45
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
25.4.2022 |
EN |
Official Journal of the European Union |
C 171/44 |
Action brought on 7 March 2022 — Biologische Heilmittel Heel v EUIPO — Esi (TRAUMGEL)
(Case T-130/22)
(2022/C 171/61)
Language in which the application was lodged: English
Parties
Applicant: Biologische Heilmittel Heel GmbH (Baden-Baden, Germany) (represented by: J. Künzel, lawyer)
Defendant: European Union Intellectual Property Office (EUIPO)
Other party to the proceedings before the Board of Appeal: Esi Srl (Albisola Superiore, Italy)
Details of the proceedings before EUIPO
Applicant of the trade mark at issue: Other party to the proceedings before the Board of Appeal
Trade mark at issue: Application for European Union figurative mark TRAUMGEL — Application for registration No 16 289 712
Procedure before EUIPO: Opposition proceedings
Contested decision: Decision of the Fourth Board of Appeal of EUIPO of 20 December 2021 in Case R 813/2021-4
Form of order sought
The applicant claims that the Court should:
— |
annul the order No. 3 of the contested decision of the Fourth Board of Appeal — R 813/2021-4 of 20 December 2021; |
— |
alter the order No. 1 of the contested decision of the Fourth Board of Appeal -R 813/2021-4 of 20 December 2021; |
— |
annul the decision of the Opposition Division of 6 April 2021 beyond the goods contained in the order No. 1 insofar as the opposition was rejected for goods in Class 3; |
— |
order the other party to the proceedings before EUIPO to pay the costs. |
Plea in law
— |
Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council. |